Compare Illumina, Inc. (ILMN) vs InMode Ltd (INMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs InMode Ltd — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while InMode Ltd trades at $14.21 (market cap $809.93M). The key difference: Illumina, Inc. is far larger — about 49.3× InMode Ltd's market cap, and Illumina, Inc. is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and InMode Ltd for 28 Days on average.
| ILMN | INMD | |
|---|---|---|
Market Cap | $39.95B | $809.93M |
Volume | 3,169,503 | 365,490 |
Sector | Health | Health |
52-Week High | $293.69 | $16.62 |
52-Week Low | $91.00 | $12.76 |
Typical Hold Time | 83 Days | 28 Days |
Enterprise Value | $41.31B | $313.27M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ILMN trades at $264.40, down 1.25% on the day, but remains near its recent 52-week high of $278.99 (Defense World, 2026-10-01). The stock has surged 94.9% year-to-date (Zacks Investment Research, 2026-09-24), supported by strong earnings beats in recent quarters and a bullish technical trend. Fundamentals show a significant turnaround, with 2025 net income reaching $850 million after prior losses, though valuation ratios like a P/E of 49.36 are elevated. The pending inclusion in the S&P 500 (PRNewsWire, 2026-09-04) adds a positive catalyst.
The outlook is positive, driven by sequencing growth, AI integration in genomics, and improved profitability. However, risks include high valuation sensitivity, cost volatility, and competitive pressures in the life sciences sector. Analyst consensus is bullish with a 54% buy rating, but the average price target of $241 suggests limited near-term upside from current levels.
InMode (INMD) trades at $14.08, up 0.5% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong profitability with 76.5% gross margins and 20.7% net income margin, though Q1 2026 earnings missed expectations. Recent developments include the launch of Morpheus8 Cool technology and an unsolicited acquisition offer from Steel Partners at $16.75 per share in July 2026.
Investment outlook is cautiously optimistic with attractive valuation metrics (P/E 11.6, EV/EBITDA 4.5) offset by near-term revenue stagnation. Key risks include US platform sales decline and management capital allocation concerns. Analyst consensus leans neutral with 45% buy ratings and 55% hold, suggesting potential upside if the acquisition materializes or international growth accelerates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →
